Articles

Find an Article

Filter articles

Applied Filters

Showing 31 to 40 of 88 results

What drives the urge to merge?

International10-10-2016

There is some debate about whether the ‘patent cliff’ or the need to innovate is driving M&A activity in the pharmaceutical industry, where billions of dollars have been spent in the past few years, as LSIPR finds out.

LSIPR 50 2016: Chunli Bai and Kyle Bass

China, US05-10-2016

Chunli Bai and Kyle Bass were selected in the LSIPR 50 2016 publication for their influence on the life sciences industry. Bai and Bass were featured in the business and innovation section, as LSIPR reports.

LSIPR 50 2016: Jorge Kalil and Narendra Modi

Brazil, India05-10-2016

Jorge Kalil and Narendra Modi were selected in the LSIPR 50 2016 publication for their influence on the life sciences industry. Kalil and Modi were featured in the government and policy section, as LSIPR reports.

LSIPR 50 2016: Jarbas Barbosa da Silva Jr and Margaret Chan

Brazil, US05-10-2016

Jarbas Barbosa da Silva Jr and Margaret Chan were selected in the LSIPR 50 2016 publication for their influence on the life sciences industry. Love featured in the government and policy section, as LSIPR reports.

LSIPR 50 2016: Xi Jinping and George Freeman

China, UK05-10-2016

Xi Jinping and George Freeman were selected in the LSIPR 50 2016 publication for their influence on the life sciences industry. Jinping and Freeman were featured in the government and policy section, as LSIPR reports.

A bright future for biologics in Thailand

Thailand08-09-2016Alan Adcock and Atthachai Homhuan

An increasing number of biologics and biosimilar products are appearing in the Thai market, but there are challenges concerning IP protection and regulation, say Alan Adcock and Atthachai Homhuan of Tilleke & Gibbins.

Easing the path for green tech in India

India11-08-2016Swarup Kumar and Jitesh Kumar

Even if India moves towards a patent-unfriendly environment for green technologies, the pro-patent and pro-environment lobbies can coexist and meet their respective goals, argue Swarup Kumar and Jitesh Kumar of Remfry & Sagar.

China v US: what can be patented in the life sciences field?

China, US09-08-2016Yu Guo

The US and China take very different approaches to the patentability of a range of inventions in the life sciences field, as Yu Guo of China Patent Agent reports.

Running an efficient clinical drug trial

International19-07-2016Charlie Nicholson

Everyone benefits from an efficiently run clinical drug study, including sponsors, contract research organisations, the investigator sites where patients are treated and observed, and most of all, patients, says Charlie Nicholson of Premier Research.

Case report: Biocon’s breast cancer biosimilar gets green light

India16-06-2016Vikrant Rana and Sanjeeta Das

In a recent decision in India, biopharma company Biocon and its partner Mylan were allowed to continue marketing a biosimilar breast cancer drug, as Vikrant Rana and Sanjeeta Das of SS Rana report.

Showing 31 to 40 of 88 results

LSIPR